Atai Life Sciences N.V. (ATAI)
After hours:
| Previous Close | 1.5200 |
| Open | 1.5200 |
| Bid | 1.5700 x 300 |
| Ask | 1.6500 x 300 |
| Day's Range | 1.4200 - 1.7100 |
| 52 Week Range | 1.0250 - 2.8500 |
| Volume | |
| Avg. Volume | 1,103,209 |
| Market Cap | 270.161M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8000 |
| Earnings Date | Nov 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.00 |
Simply Wall St.Oxbridge Re Holdings Among 3 US Penny Stocks To Watch
The U.S. stock market has recently shown signs of recovery, with the S&P 500 and Nasdaq Composite rebounding after a challenging week, highlighting the resilience of equities amid fluctuating investor sentiment. Penny stocks may be an older term, but they continue to offer intriguing investment opportunities by allowing investors to access potential growth in smaller or newer companies at lower price points. When these stocks are supported by strong financial health and solid fundamentals,...
GlobeNewswireatai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE’24 - Remain on track to initiate a Phase 2 study of EMP-01 (oral R-MDMA) in social anxiety disorder patients around YE’24 - Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) --
